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Background: PROSTVACW, an active immunotherapy currently studied for the treatment of metastatic castration-resistant
prostate cancer (mCRPC), consists of a heterologous prime-boost regimen with two different poxvirus-based vectors to
provoke productive immune responses against prostate specific antigen (PSA) as the target tumor antigen. A Phase 2
study of PROSTVAC immunotherapy showed significantly improved median overall survival by 8.5 months and is currently
being validated in a global Phase 3 study (PROSPECT; NCT01322490). Here, preclinical models were explored to
investigate the mechanism of action and immune signatures of anti-tumor efficacy with PROSTVAC immunotherapy
with the goal to identify potential immune correlates of clinical benefit.
Methods: PROSTVAC-induced immune responses and anti-tumor efficacy were studied in male BALB/c mice. Functionality
of the induced T cell response was characterized by interferon-gamma (IFNγ) ELISPOT, cytotoxic degranulation,
multi-cytokine intracellular staining, and in vivo T cell depletion. Tumor infiltrating lymphocytes (TILs) were evaluated
phenotypically by flow cytometry.
Results: The heterologous prime-boost regimen of the two PROSTVAC vectors significantly enhanced the magnitude
and quality of activated PSA-specific CD4 and CD8 T cell responses compared to homologous, single vector regimens.
PROSTVAC-activated CD4 and CD8 T cells were highly functional as evidenced by expression of activation markers,
production of multiple cytokines, and amplified cytotoxic T cell activity. Importantly, PROSTVAC immunotherapy
resulted in significant anti-tumor efficacy in a transplantable prostate cancer mouse model. Antigen-spreading
occurred in PROSTVAC-treated animals that rejected PSA-expressing tumors, as shown by subsequent rejection
of PSA-negative tumors. In vivo CD4 and CD8 depletion revealed that both T cell subsets contributed to anti-tumor
efficacy. Characterization of TILs demonstrated that PROSTVAC immunotherapy greatly increased the intra-tumoral ratio
of activated effector to regulatory T cells.
Conclusions: PROSTVAC immunotherapy activates broad, highly functional T cell immunity to PSA and to endogenous
tumor antigens via immune-mediated antigen spreading. These preclinical results further elucidate the mode of action
of PROSTVAC immunotherapy and its potential causal relationship to extended overall survival as observed in the
PROSTVAC Phase 2 study. The clinical validation is ongoing in the PROSPECT Phase 3 clinical study.
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PROSTVACW is a PSA-targeted active immunotherapy
composed of a heterologous prime-boost regimen using
two poxviral-based vectors: PROSTVAC-V™, a recom-
binant vaccinia virus, and PROSTVAC-F™, a recombinant
fowlpox virus. Both vectors contain transgenes for human
prostate-specific antigen (PSA) and three co-stimulatory
molecules for T cells (B7.1, ICAM-1, and LFA-3, desig-
nated as TRICOM) to enhance immune activation [1]. A
robust data package for PROSTVAC has been generated
through 8 completed Phase 1 and Phase 2 clinical trials,
where more than 300 patients have been treated. The
PROSTVAC immunotherapy regimen is well-tolerated,
with grade 2 or less injection site reactions being most
common [2]. A randomized, placebo-controlled Phase
2 study in patients with asymptomatic or minimally symp-
tomatic mCRPC used the heterologous prime-boost strat-
egy composed of a single PROSTVAC-V priming dose
followed by six PROSTVAC-F boosts. All virus treatments
were given in combination with low-dose recombinant
GM-CSF. This study demonstrated the potential ability of
PROSTVAC to extend the median overall survival by
8.5 months in patients with advanced prostate cancer
(25.1 months vs. 16.6 months for controls) and reduced
the death rate by 44% [3]. By comparison, the clinical stud-
ies supporting FDA approval of sipuleucel-T for mCRPC
improved the median overall survival by 4.1 months [4].
An international Phase 3 study (PROSPECT) is currently
ongoing to validate the randomized Phase 2 data with
PROSTVAC for the treatment of men with mCRPC.
Concurrently, PROSTVAC is being investigated in NCI-
sponsored clinical studies in different stages of prostate
cancer and in combination with other anticancer agents,
such as anti-androgens, local radiation, targeted small
molecule drugs, and immune checkpoint inhibitors [5].
Throughout the various Phase 1 and Phase 2 studies
performed with PROSTVAC and its precursors, immune
monitoring has been performed and the collective data
on the immune impact of PROSTVAC has recently been
published by Gulley et al [2]. For example, findings of a
small Phase 2 study (n = 32) investigating the influence
of immunologic and prognostic factors on overall sur-
vival suggested that patients who mounted the highest
increase (>6 fold as compared to baseline) in PSA-
specific T cell responses pre and post PROSTVAC treat-
ment, showed improved survival compared with patients
that did not mount as great a response [6]. Additionally,
patients surviving longer than predicted by Halabi nomo-
gram showed a decrease in the suppressive function of
CD4 T regulatory (Treg) cells while it was increased in pa-
tients surviving shorter than predicted. Overall, this
study suggested that patients with more indolent mCRPC
(Halabi predicted survival >18 months) may best benefit
from PROSTVAC immunotherapy [2,6,7].The data for potential immune correlates of improved
clinical benefit, while revealing and hypothesis-generating
for prospective analyses, were generated retrospectively
from a small subset of all subjects. Moreover, most ELI-
SPOT assays to date used a single 9-mer peptide repre-
senting only the T cell responses of patients with the
HLA-A2 allele, and tumor tissue for the evaluation of
tumor-infiltrating immune responses after subcutaneous
dosing with PROSTVAC was not available. Hence, more
work is needed to establish a correlation between immune
responses and improved overall survival.
PROSTVAC-V/F immunotherapy is a complex biologic
that has been developed in an iterative fashion in parallel
with other vectors expressing CEA as tumor associated anti-
gens. Using vectors that express human CEA and mouse
TRICOM molecules in the context of CEA-transgenic mice
it has been demonstrated that poxvirus-based immuno-
therapy can overcome tolerance and result in significant
anti-tumor efficacy against transplanted and spontaneously
arising tumors [8-10].
The data presented here employed the PROSTVAC-V/F
heterologous prime-boost regimen in WT BALB/c mice,
which allowed for an in-depth characterization of peripheral
and tumor-infiltrating T cell responses induced by the
PROSTVAC immunotherapy for the first time. Our data
not only support the previous clinical immunological data,
but also provide additional mechanistic evidence that has
been lacking from clinical studies. PROSTVAC immuno-
therapy induced polyfunctional PSA-specific T cells, resulted
in the infiltration of Tcells into tumors, required CD8 Tcells
for anti-tumor efficacy, and led to antigen spreading which
protected mice from re-challenge with tumor cells that
lacked PSA expression. Our data provide insight towards
prospective and retrospective analyses exploring the role of
PROSTVAC immunotherapy for improved clinical benefit.
Results
Heterologous prime-boost strategy increases the magnitude
and quality of PSA-specific CD4 and CD8 T cell responses
The PROSTVAC-V/F dosing regimen in the PROSPECT
Phase 3 study comprises a heterologous prime-boost regi-
men consisting of a single prime with PROSTVAC-V
followed by six consecutive doses of PROSTVAC-F [3].
The regimens in mouse studies described here were per-
formed with a maximum of three homologous vector
doses or one priming plus two heterologous vector doses.
Male BALB/c mice were immunized three times with
PROSTVAC-V (VVV), three times with PROSTVAC-F
(FFF), or were primed with PROSTVAC-V, followed by
booster doses of PROSTVAC-F (VFF). Two weeks after
the last dose, PSA-specific immune responses were evalu-
ated by IFNγ ELISPOT, CTL degranulation assay, and
ELISA (Figure 1; for comparison, vector-specific responses
can be found in the Additional file 1: Figure SD1).
γ
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Figure 1 Heterologous prime-boost amplifies PSA-specific T cell responses. BALB/c males (5/group) were treated every two weeks with:
buffer (Control), PROSTVAC-V (VVV), PROSTVAC-F (FFF) or received a PROSTVAC-V prime followed by 2 PROSTVAC-F boosts (VFF). Pooled splenocytes
were assayed for PSA-specific responses by IFNγ ELISPOT (A, B) and cytotoxic activity by flow cytometry (% CD107+ IFNγ+ CD8 T cells) (C). Anti-PSA
IgG titers were determined by ELISA for each individual mouse (D). For ELISPOT, splenocytes were restimulated with CD4 or CD8 PSA-specific peptides
or controls (controls not shown) at indicated concentrations. Responses that were too numerous to count were displayed as 1000 spots/million cells.
Statistical significance was determined by Two-way-ANOVA with Tukey post-test at 0.01 μM. ****P < 0.001 compared to control or homologous dosing
(A & B). To identify cytotoxic CD8+ T cells, splenocytes were restimulated overnight with a PSA CD8-specific peptide in the presence of anti-CD107
antibody. Graphs show representative data of four independently performed experiments.
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a much higher frequency of IFNγ-producing PSA-specific
CD4 T cells (Figure 1A) and CD8 T cells (Figure 1B and
Figure 2A) compared to VVV or FFF homologous dosing
regimens. Moreover, PSA-specific T cells from VFF dosing
were of higher avidity (Figure 1A & B), as evidenced by
higher frequencies of T cells responding at the lower
0.01 μM peptide concentrations in the ELISPOT. Import-
antly, the number of functionally active PSA-specific CD8
CTLs resulting from the VFF heterologous prime-boost
regimen was 7 to 20 fold higher than those generated by
either homologous dosing regimen (Figure 1C). In con-
trast to the T cell responses, the heterologous prime-boost
regimen did not improve PSA-specific antibody responses
(Figure 1D). These results indicate that heterologous VFF
dosing generates CD4 and CD8 PSA-specific T cell re-
sponses of greater magnitude and higher quality as measuredby higher avidity and increased CD8 CTL activity. These
traits would contribute to improved anti-PSA specific anti-
tumor responses following heterologous PROSTVAC-V/F
dosing.
Additional distinguishing features in the quality of the
PSA-specific CD8 Tcell response were observed when PSA-
specific CD8 T cells were analyzed for the multicytokine-
production of IFNγ, TNFα, and IL-2 by flow cytometry
(Figure 2). Using cytokine expression, CD8 memory Tcells
have been classified as double-positive CD8 T cells (IFNγ +
TNFα+, represented in green) and as triple-positive CD8
T cells (IFNγ + TNFα + IL-2+, represented in red) [11].
In addition to the increased magnitude of the CD8 T
cell response (Figure 1 and Figure 2A), a pronounced
shift in the quality of the CD8 T cell response was re-
vealed. Particularly a higher proportion of double-
positive T cells (56% for VFF as compared to 25%
Figure 2 Heterologous prime-boost improves the quality of PSA-specific T cell responses. BALB/c mice (6/group) were treated as
described for Figure 1. Spleens were harvested 14 days after the last treatment, and pooled splenocytes were restimulated overnight with PSA
OPL or controls (controls not shown). The cells were stained for intracellular IFNγ, TNFα, and IL-2 prior to flow cytometric analysis. (A) The pie
charts are weighted in size to reflect the numbers of detected cells (total numbers of PSA-specific CD8 per million T cells are indicated below
each chart, % of respective T cell populations can be found in Additional file 1: Table SD1). (B) Amount of IFNγ production on a per cell basis as
measured by mean fluorescence intensity (MFI). Graphs show representative data of two independently performed experiments.
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PROSTVAC-V/F regimen compared to homologous
dosing regimen (Figure 2A and Additional file 1: Table SD1).
The percent of triple-positive PSA-specific Tcells was similar
in the VVV and VFF groups but higher as compared to FFF
treatment. Priming with a 5 fold higher PROSTVAC-V dose
did not yield any additional benefit in the magnitude or the
quality of the CD8 T cell response (see Additional file 1:
Figure SD2 and Table SD1). The increased production of
IFNγ by multicytokine-producing cells has been linked to
better protection against various infectious diseases [12]. In-
deed, double-positive and triple-positive PSA-specific CD8 T
cells produced higher levels of IFNγ on a per cell basis than
single positive cells (Figure 2B). This increased IFNγ produc-
tion was observed in double and triple positive CD8 T cells
regardless of dosing regimen.
Heterologous prime-boost regimen focuses the CD8 effector
response towards the tumor antigen
Two additional T cell markers are regularly used to
characterize highly functional CD8 effector T cell subsets,
the CD127 (IL-7R alpha chain) memory T cell marker and
the effector T cell marker killer lectin-like receptor G1
(KLRG-1) [13]. Short-lived effector CD8 T cells (SLECs)
are characterized as KLRG-1+ CD127- CD8 T cells while
double positive effector cells (DPECs) are characterized as
KLRG1+ CD127+ CD8 T cells [14]. DPECs haverecently been identified as a highly functional effector-like
memory T cell subset [15]. The impact of heterologous
PROSTVAC-V/F dosing compared to homologous dosing
on the cytotoxic capabilities of vector-specific vs. PSA-
specific effector T cell subsets was analyzed by flow cy-
tometry. Homologous VVV dosing generated a relatively
high number of vaccinia-specific cytotoxic SLEC (~50%)
and DPEC (~20%) (Figures 3A, 3C), yet less than 10% of
SLEC or DPEC cytotoxic CD8 T cells were PSA-specific.
Conversely, 65% of SLEC and 30% of the highly active
DPEC effector memory T cells were PSA-specific CTL fol-
lowing heterologous VFF dosing, while less than 10% con-
stituted vaccinia-specific CTL (Figure 3A, 3C). Therefore,
the heterologous PROSTVAC-V/F regimen resulted in a
100 fold improvement in the ratio of PSA-targeted
to vaccinia-targeted SLEC and DPEC T cell responses
(Figures 3B and D). Again, priming with 5 fold more
PROSTVAC-V did not yield any additional benefit (data
not shown).
The data shown in Figures 1, 2 and 3 revealed that the
heterologous PROSTVAC-V/F regimen greatly enhances
the magnitude and quality of the PSA-specific T cell re-
sponse compared to homologous dosing with the same
vector. Of note, a distinctive phenotype of activated, highly
functional SLEC and DPEC was induced while priming
with PROSTVAC-V and boosting with PROSTVAC-F pro-
vided the added benefit of focusing the highly functional
Figure 3 Immune focusing of T cell response towards PSA. Mice were treated as described for Figure 1. Pooled splenocytes were assayed for
vaccinia virus (VV)-specific (A and C panels on left) or PSA-specific (A and C panels on right) cytotoxic activity by flow cytometry (% CD107+ IFNγ+ CD8 T
cells) 14 days after the last treatment. Splenocytes were restimulated overnight with vaccinia E3L and F2L peptides or with PSA OPL (or PSA peptide
HPQKVTKFML, see Additional file 1: Figure SD4) in the presence of anti-CD107 antibody. The following day, cells were stained intracellularly for IFNγ and
with the surface markers CD127 and KLRG1.% antigen-specific cytotoxic SLEC and DPEC were determined by gating on (CD8 + CD127-KLRG1+) and
(CD8 + CD127 + KLRG1+) cells, respectively. (B, D)The PSA:VV ratio was determined by dividing % CD107+ IFNγ + PSA-specific DPECs or SLECs by %
CD107+ IFNγ + VV-specific DPECs or SLECs. Graphs show representative data of two independently performed experiments. Similar responses
were observed when splenocytes were restimulated with PSA peptide HPQKVTKFML instead of a PSA OPL (Additional file 1: Figure SD4). The gating
strategy for these experiments is outlined in Additional file 1: Figure SD3).
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tumor antigen, and away from the vaccinia vector.
Heterologous PROSTVAC-V/F dosing induces significant
anti-tumor efficacy and antigen-spreading in a mouse
prostate cancer model
The anti-tumor activity of heterologous PROSTVAC-V/
F immunotherapy was confirmed in a mouse prostate
cancer model using transplanted RM-11-PSA cells. Mice
were challenged with tumors and subsequently dosed
with a regimen of heterologous wild-type (WT) parental
virus vectors with no transgenes, with heterologous UV-
inactivated PROSTVAC-V/F or heterologous PROSTVAC-
V/F active immunotherapy (Figures 4A). The dosing
regimen was accelerated to weekly administration due
to the rapid growth kinetics of this tumor model. The
anti-tumor response was dependent on dosing withactive viral vectors, since no efficacy was observed
with UV-inactivated viruses (Figure 4A). Although a
visible trend in anti-tumor activity was noted within a
100 fold PROSTVAC-V/F dose range (Additional file 1:
Figure SD5), the efficacy of PROSTVAC-V/F immuno-
therapy, compared to dosing with empty vectors (2E7/1E8
WT controls), was statistically equivalent over that 100
fold dose range. For all follow on studies, the highest dose
of 2E7/1E8 VFF was used.
In Figure 4A, all dosing was accompanied by immunization
with 1E7 Inf.U of recombinant fowlpox virus encoding
murine GM-CSF (rFP GM-CSF). This dose has been
shown to have similar activity as recombinant GM-CSF in
mouse models [16]. Recombinant GM-CSF was used in
the Phase 2 clinical trial that resulted in improved median
overall survival of 8.5 month in men with mCRPC [3].
However, the necessity of GM-CSF for the efficacy of
Figure 4 PROSTVAC mediated anti-tumor efficacy and antigen spreading. (A & B) BALB/c mice (10-20/group) were challenged by i.d. injection
of RM-11-PSA cells on day 1 and treated 3 times at weekly intervals as described in text. Graphs show data from 2 independently performed experiments.
(C) Previously-challenged, tumor-free PROSTVAC V/F-treated mice (n = 6) and naïve BALB/c (n = 10) were injected i.d. with 2E5 RM11-WT
cells. ****P < 0.0001.
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comparison of PROSTVAC-V/F immunotherapy with and
without rFP GM-CSF is shown in Figure 4B. Anti-tumor
efficacy was observed whether or not murine GM-CSF was
co-administered with PROSTVAC-V/F (Figure 4B). Treat-
ment with the rFP GM-CSF vector alone had no effect on
tumor growth.
As shown in Figure 4A, the anti-tumor efficacy in the
RM-11-PSA model was unequivocally dependent on a
productive immune response against the vector-encoded
PSA tumor antigen compared to WT parent vectors.
The requirement for a response to the delivered tumor
antigen highlights the contribution of the adaptive im-
mune response to anti-tumor efficacy. Successive induc-
tion of T cell immune responses against endogenous
tumor antigens not encoded by the vector (antigen spread-
ing) has gained attention as a crucial component for effect-
ive, long-lasting tumor surveillance in addition to the
transgene specific anti-tumor activity [17,18]. To test if
adaptive immune responses initiated by PROSTVAC ther-
apy had spread to other antigens, mice were implanted
with RM-11-PSA tumor cells and treated with PROSTVAC
or control buffer as described before. Six out of 20 mice
completely rejected the tumor (data of individual mice of
this experiment are shown in Additional file 1: Figure SD6).
Animals that rejected PSA-expressing tumors were subse-
quently re-challenged with a lethal dose of parental RM-
11-WT tumors that lack PSA expression. All re-challenged
mice completely rejected the parental tumors whilenaïve mice challenged with the same parental tumor
cells succumbed within 18 days (Figure 4C). These data
confirm that PROSTVAC-V/F immunotherapy induced
antigen-spreading as a consequence of active anti-cancer
PSA-specific T cell responses. While the target antigens of
the T cells that contributed to the de novo anti-tumor effi-
cacy were not determined, these results demonstrated that
the protective immunity elicited by PROSTVAC immuno-
therapy expanded to include antigen-spreading beyond
the robust PSA-specific T cell immune responses identi-
fied in Figures 1, 2 and 3.
Tumor infiltrating PSA-specific CD8 and CD4 T lymphocytes
contribute to anti-tumor efficacy
The infiltration of highly functional antigen-specific
CTLs into the tumor coupled with overcoming the regu-
latory CD4 T cell environment in the tumor are consid-
ered to be key drivers for optimal anti-tumor efficacy
[19]. To explore the contributions of CD4 and CD8 TILs
to anti-tumor efficacy, heterologous PROSTVAC-V/F
immunotherapy was performed in mice that were select-
ively depleted of CD8 T cells (Figure 5A) or CD4 T cells
(Figure 5D). Tumors were subsequently isolated and
the phenotype of TILs was analyzed by flow cytometry
(Figure 5B and C for CD8 depletion and Figure 5E and
F for CD4 depletion).
As shown before (Figure 4A and B), heterologous
PROSTVAC immunotherapy resulted in significant delay
of tumor growth as compared to control-treated animals
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Figure 5 Anti-tumor efficacy in CD4 or CD8 T cell depleted mice and analysis of TILs. Selected groups of BALB/c mice (10/group) were
injected i.p. with either anti-CD8 (A) or anti-CD4 antibodies (D) prior to tumor cell challenge and throughout the study. Mice were treated 3 times
at weekly intervals starting on day 1. **P < 0.01, ****P < 0.0001 as compared to control. At the end of the study, tumors were removed and TILs
were analysed by flow cytometry. CD8 (B and E) and CD4 (C and F) T cells are shown as a percentage of cells isolated from the tumors. Graphs
show representative data from two independently performed experiments.
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acterized by the infiltration of the tumor by CD8 T cells
(see VFF, Figure 5B and 5E) and CD4 T cells (see VFF,
Figure 5C and 5F) at approximately a 2:1 ratio of CD8
to CD4 T cells. The depletion of CD8 T cells completely
abrogated PROSTVAC-mediated anti-tumor efficacy,
demonstrating the importance of PROSTVAC-induced
CD8 effector cells. As expected, no CD8 T cells were
found in CD8-depleted animals (Figure 5B), and this
may explain why tumors grew more aggressively at
later time points in these animals compared to con-
trols. In addition, fewer CD4 T cells infiltrated thetumor of CD8-depleted animals (Figure 5C), suggest-
ing that CD8 T cells aid in the recruitment of CD4 T
cells into the tumor.
CD4 T cell depletion alone also had an impact on
tumor growth and significantly increased the aggressive-
ness of the tumor model in the absence of PROSTVAC
treatment. TIL analysis showed that no CD4 and very
few CD8 T cells could be found in tumors of CD4-
depleted animals (Figure 5E and F). Importantly, the
impact of CD4 depletion was partially overcome by
PROSTVAC immunotherapy (Figure 5D). Albeit not
as effective as in fully immune-competent animals,
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http://www.immunotherapyofcancer.org/content/2/1/34PROSTVAC immunotherapy in the absence of CD4 T
cells significantly reduced tumor growth as compared
to CD4-depleted animals (VFF + anti-CD4 vs. anti-
CD4). Subsequent TIL analysis revealed that PROST-
VAC dosing had, even in the absence of CD4 T cells,
recruited CD8 effector T cells into the tumor suggest-
ing that PROSTVAC immunotherapy activated and re-
cruited CD8 T cell infiltration independently of CD4 T
cell help (VFF + anti-CD4, Figure 5E). These findings
suggest that PROSTVAC immunotherapy allows for
CD4-dependent and CD4-independent CD8 effector T
cell generation.
PROSTVAC immunotherapy recruits highly functional
effector T cells into the tumor, while overcoming the
tumor-associated Treg environment
The robust infiltration of CD4 and CD8 T cells into the
tumor following PROSTVAC immunotherapy is critical
for productive anti-cancer immunity. However, the pres-
ence of Treg cells in the tumor environment is recog-
nized to hamper the development of effective anti-tumor
responses [19-23].
To confirm that PROSTVAC immunotherapy induced
a productive and functional tumor-infiltrating T cell re-
sponse, CD8 and CD4 TILs were analyzed for effector1
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http://www.immunotherapyofcancer.org/content/2/1/34to an average of 12% of CD4 TILs in PROSTVAC-V/
F-treated animals (data not shown). A similar trend was
also observed when ICOS was used as an additional marker
on Treg (30% in controls vs. 12% in treated animals,
Additional file 1: Figure SD7 and data not shown). Since
the highly functional TILs resulting from PROSTVAC im-
munotherapy greatly outnumbered the tumor-associated
regulatory CD4 Treg population, PROSTVAC immuno-
therapy considerably increased the ratios of CD4 and CD8
effector T cells to suppressive Treg cells (Teff : Treg ratio)
in the tumors (Figure 6B and C). These data demonstrate
that PROSTVAC immunotherapy improves the intratu-
moral balance of effector to regulatory T cells. Together
these data reveal the mechanisms of PROSTVAC immuno-
therapy for eliciting significant, highly productive anti-
tumor immune responses.Discussion
The preclinical studies in this work interrogated the
immune signature generated by the heterologous prime-
boost regimen and the mechanism of action of PROST-
VAC immunotherapy in preclinical mouse models. We
used a combination of functional assays and flow cyto-
metry to characterize PSA-specific T cell responses in-
duced by PROSTVAC treatment. Our data show that
PROSTVAC treatment induced polyfunctional PSA-specific
T cell responses as measured by IFNγ ELISPOT, multicyto-
kine production and PSA-specific cytotoxic activity. The
heterologous prime-boost regimen increased the magnitude
of the PSA-specific Tcell response as well as markedly chan-
ging the quality of the T cell response. Animals that received
the heterologous prime-boost regimen showed higher per-
centages of IFNγ TNFα double -positive or IFNγ TNFα
IL-2 triple-positive CD8 T cells. These cells have been de-
scribed by Seder et al as double-positive effector memory
(TEM) cells or triple-positive central memory (TCM) cells
[11,24]. Besides the expression of IL-2, additional markers
typically distinguish these T cell subsets. TCM have a high
proliferative potential, recirculate preferentially through
lymph nodes, and require a relatively longer time to be-
come cytotoxic. TEM, in contrast, have a less proliferative
potential, recirculate preferentially through non-lymphoid
tissues, and are immediately cytotoxic upon antigen re-
exposure. Both T cell memory subsets have been reported
to contribute effectively to protection from infectious dis-
ease, depending on the route, dose, replication rate and
tropism of the infectious challenge [25]. Less is known
about the relative contributions of these T cell subsets to
productive immunity against cancer, but it is feasible to
assume that polyfunctional CD8 T cells will prove to be
more efficient in cancer immunotherapy. Higher percent-
ages of CD8 T cells in the tumor have been correlated
with better prognosis for a variety of cancers [26,27].CD8 T cells phenotyped by CD127 and KLRG-1 bio-
markers showed that poxvirus-based immunotherapy
potently induces peripheral and tumor-infiltrating SLECs
and DPECs which are activated effector cells with cyto-
toxic activity [28]. Although limitations in cell number
prevented us from performing functional assays on the
TILs, we believe that the phenotypic similarities of these
highly activated (CD44+ and ICOS+) CD8 T cells add
suggestive evidence that these cells have similar func-
tional capabilities as the cells described in Figures 1, 2
and 3. Cytotoxic activity of TIL has been demonstrated
by us in a different tumor model using a similar poxvirus-
based immunotherapy product [29]. It is of note that the
heterologous PROSTVAC prime-boost regimen increases
the ratio of PSA-targeted to vaccinia-targeted CTL re-
sponses more than 100 fold compared to a homologous
dosing regimen. These data are consistent with and may
help explain the results from a Phase 2 clinical study in-
vestigating PROSTVAC dosing regimens. In that study,
progression-free clinical benefit was much better in the
cohort of men administered PROSTVAC-V as a priming
dose followed by boosting with subsequent PROSTVAC-F
doses (VFFF) over other regimens of PROSTVAC-F
followed by PROSTVAC-V (FFFV), or homologous re-
peated FFFF doses with PROSTVAC-F [30].
Anti-tumor efficacy in the mouse model described here
was dependent on live virus and the expression of PSA,
but not on the co-administration of GM-CSF. Although
low-dose recombinant GM-CSF was co-administered with
PROSTVAC in the Phase 2 study showing improved over-
all survival in men with mCRPC, it is unclear what benefit
was contributed by the addition of GM-CSF. Data from a
Phase 2 study similar to that shown in Figure 4B also indi-
cate that the clinical benefit for men with mCRPC
treated with PROSTVAC may not be dependent on the
co-administration with GM-CSF [6]. To test this hy-
pothesis, the PROSPECT Phase 3 trial comprises two
PROSTVAC treatment arms, i.e. with and without con-
comitant GM-CSF.
The use of a mouse model allowed us to investigate
the mechanism of action of the observed anti-tumor ac-
tivity more deeply by enabling in vivo depletion of T cell
subsets and examination of TILs. In vivo depletions of
CD8 and CD4 T cells confirmed that CD8 T cells are re-
quired and CD4 T cells are necessary for optimal anti-
tumor efficacy. Importantly, it also demonstrated that
CD4-dependent and independent mechanisms for the
generation of CD8 T cells may exist. Phenotypic analysis
of TILs demonstrated that the endogenous immune re-
sponse to the tumor is weak in this model, although a
low percentage CD4 and CD8 T cells could be detected.
PROSTVAC immunotherapy, in contrast, increased tumor
infiltration by CD8 and CD4 T cells more than 10-fold.
More importantly, SLECs and DPECs were found in the
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bered the tumor-associated regulatory CD4 Treg popula-
tion, resulting in much improved Teff : Treg ratios in the
tumor microenvironment. Although PSA is a foreign anti-
gen in the mice used here, the results found can be ex-
pected to apply towards tolerant transgenic mice where
poxviral immunotherapy has already been demonstrated to
be effective, despite having a lower magnitude response
in transgenic compared to wild-type mice. Anti-tumor
efficacy of poxvirus-based immunotherapy against an
immune tolerant tumor associated antigen (TAA) has
been demonstrated with a related poxvirus-based im-
munotherapy expressing CEA. Those studies, performed
in CEA-transgenic mice (where CEA is viewed by the
immune system as a self-antigen) demonstrated, that
anti-tumor efficacy following immunization with CEA/
TRICOM vectors was largely due to treatment-induced
T cell responses and occurred in the absence of auto-
immunity [31]. Another study using PSA-transgenic mice,
demonstrated that a single treatment with recombinant
vaccinia virus expressing PSA could induce PSA-specific
T cells and this response was augmented by androgen
ablation [32]. Furthermore, preliminary data from one
clinical study [33] revealed a significant decrease in
Treg relative to CD4 positive cells within the tumor
following intraprostatic administration of PROSTVAC-F.
In other studies where PROSTVAC immunotherapy was
given s.c. [6], there was a strong trend in changes in Treg
function pre- versus post- PROSTVAC immunotherapy.
Patients who survived longer than predicted by the Halabi
nomogram had decreased Treg suppressive function after
receiving PROSTVAC (log-rank P = 0.058).
Antigen spreading is the development of immune re-
sponses to TAA found on the tumor but not expressed
by the poxvirus-based vector. Our data demonstrate that
PROSTVAC immunotherapy induced antigen spreading
from the originally targeted PSA to unknown antigens
expressed by the parenteral mouse prostate cancer cell
line. Importantly, evidence of antigen spreading has also
been found in clinical studies where T cell responses to
MUC-1, PSMA, PAP and other TAA have been detected
in more than 50% of the analyzed patients [34-37].
Monitoring of these antigen spread responses may be
of great value as an immune correlate for a successful
anti-tumor response.
Conclusions
In summary, we have generated preclinical evidence sup-
porting the PROSTVAC mechanism of action and have
identified potential immune correlates for anti-tumor ef-
ficacy using poxvirus-based immunotherapy in mice.
These hypothesis-generating data will be applied to the
retrospective and prospective analyses of clinical trials
employing PROSTVAC and other poxvirus-basedimmunotherapies either alone or in combination with
other therapies.
Methods
Viruses
The PROSTVAC vaccinia vector (PROSTVAC-V), fowl-
pox vector (PROSTVAC-F) and wild-type (WT) fowlpox
(TBC-FPV) were produced by Bavarian Nordic (BN) at
IDT Biologika (IDT, Dessau-Rosslau, Germany). A prep-
aration of Dryvax was used for WT vaccinia virus (New
York City Board of Health (NYCBH) Wyeth Strain, seed
stock provided by the Centers for Disease Control and
Prevention; manufactured by the former Therion Biologics
Corp., Cambridge, MA). Fowlpox-muGM-CSF (rFP GM-
CSF) is a recombinant fowlpox virus expressing mouse
granulocyte-macrophage colony stimulating factor [16]
and was produced by BN (Martinsried, Germany). The
infectious unit titers (Inf.U/mL) of viral stocks were
determined using flow cytometry [38]. Inactive virus
particles were generated by exposing preparations to
UV light for 20-40 minutes. The integrity of the inacti-
vated virus particles was confirmed by Nanoparticle
Tracking Analysis (data not shown; [39]).
Proteins and peptides
The following peptides were synthesized by and pur-
chased from JPT Peptide Technologies, Inc. (Acton,
MA): PSA overlapping peptide library (PSA OPL),
PSA-specific CD8 peptides (AQVHPQKVTKFMLCA and
PQKVTKFMLCAGRWT for ELISPOT or HPQKVTKFML
[11] for flow cytometry), PSA-specific CD4 peptides (PERP-
SLYTKVVHYRK and SLYTKVVHYRKWIKD), vaccinia
E3L and F2L peptides (VGPSNSPTF and SPGAAGYDL
[40]). The HER2-derived peptide p63 (TYLPTNASL [41])
was used as a negative control. PSA protein was pur-
chased from Meridian Life ScienceW, Inc. (Memphis, TN).
In vivo studies
Male BALB/c mice aged 6-8 weeks old were obtained
from Simonsen Laboratories (Gilroy, CA). In non-tumor
challenged studies, virus treatments were given sub-
cutaneously (s.c.) on days 1, 15, and 29. Mice were
dosed with either 2E6 Inf.U PROSTVAC-V, 1E7 Inf.U
PROSTVAC-F or buffer as indicated in the results.
Antibody titers were determined by ELISA, and the
frequency of IFNγ producing T cells was determined
by ELISPOT as described previously [42]. Animals re-
ceived food and water ad libitum and were maintained
according to BN IACUC guidelines.
For tumor challenge experiments, the mouse prostate
cancer derived RM-11-PSA clone E6 [43] was expanded
in vitro and 1.5E5 E6 cells were implanted intradermally
(i.d.) in 100 μL DPBS on day 1. Mice were treated on
days 1, 8, and 15 with 2E7/1E8 Inf.U WT vaccinia/WT
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PROSTVAC-V/F with 1E7 Inf.U of Fowlpox-muGM-
CSF, or volumes equivalent to 2E7/1E8 Inf.U of UV-
treated PROSTVAC-V/F. Tumor growth was measured
twice a week using calipers. Tumor volume (mm3) was
calculated using the formula: V = (LxW2)/2, L = length,
W = width (1 mm3 = 1 mg). For each treatment group,
mean tumor sizes were calculated. Error bars represent
standard error of the mean (SEM). Statistical significance
over the course of the measurements was determined by
Repeated Measure ANOVA (RM-ANOVA) with a mul-
tiple comparison post-test (Tukey for 3 or more groups
and Sidak for 2 groups). For depletion studies, mice were
treated intraperitoneally (i.p.) on days -3, 5, 12, and 19
with anti-CD4 (GK1.5), anti-CD8 (2.43) or isotype control
antibodies from BioXCell (West Lebanon, NH).
Flow cytometry
Spleens and solid tumors were collected for flow cytomet-
ric analysis. Cell suspensions of the spleen were prepared
by gently grinding the tissue between the frosted ends of
glass microscope slides in RPMI-10: RPMI-1640 (Corning,
Manassas, VA), 10% FBS (Corning), 1% penicillin/strepto-
mycin (Corning), and 0.55 μM β-Mercaptoethanol (Life
Technologies, Carlsbad, CA). Splenocytes were treated
with ACK lysing buffer (Lonza, Allendale, NJ). Solid tu-
mors were diced to ~1-2 mm3 pieces and further digested
to single cell suspensions for 1 h at 37°C in RPMI-10
with 50 U/mL DNAse I and 250 U/mL Collagenase I
(Worthington Biochemical Corporation, Lakewood, NJ).
Red blood cells were lysed with RBC Lysis Buffer
(eBioscience, San Diego, CA).
Antibodies used for flow cytometry (clone number in
parentheses): CD3 (500A2), CD4 (RM4-5), CD8a (53-
6.7), CD107a (1D4B), KLRG1 (2 F1), CD44 (clone IM7),
CD62L (MEL-14), and IFNγ (XMG1.2), from BD Biosci-
ences (San Jose, CA). CD3 (145-2C11), CD127 (A7R34),
CD4 (RM4-5), CD8 (53-6.7), IL-2 (JES6-5H4), IFNγ
(XMG1.2), and TNFα (MP6-XT22) from BioLegend (San
Diego, CA). CD4 (RM4-5), ICOS (7E.17G9), FoxP3
(FJK-16 s) and FC receptor block CD16/32 (93) from
eBioscience. Flow cytometry was performed on the LSR
II (BD Biosciences) and analyzed using FlowJo version
9 (TreeStar, Ashland, OR).
To characterize antigen-specific cytotoxic T lympho-
cytes (CTL), an activation-induced degranulation assay
was used [44] to identify CD107a+ IFNγ+ CD8 T cells.
Splenocytes were plated at 2E6 cells per well in RPMI-
10 and cells were stimulated overnight at 37°C with
antigen-specific peptides, 1 μM human p63 (an irrele-
vant peptide control), 5 μg/mL Concanavalin A (MP
Biomedicals, Santa Ana, CA), or RPMI-10 in the pres-
ence of anti-CD107a and GolgiStop™ (BD Biosciences).
The following day, the cells were washed, blocked withFC-block and stained for surface markers. Cells were then
stained intracellularly for IFNγ using the BD Cytofix/
Cytoperm™ kit (BD Biosciences). Additional intracellular
cytokine staining was performed on splenocytes to detect
IFNγ, TNFα, IL-2, and IL-4. Cells were stimulated over-
night with antigen-specific peptides, 1 μM human p63 as
negative control, 2 nM PMA/1 μM ionomycin (Acros Or-
ganics, Lawndale, NJ and Sigma-Aldrich, St. Louis,
MO) or RPMI-10 in the presence of GolgiStop™ and
Golgi Plug™ (BD Biosciences) and stained as previously
described.
Regulatory T cells were identified by staining intracel-
lularly for FoxP3 using the FoxP3/Transcription Factor
Staining Buffer Set from eBioscience following the man-
ufacturer’s instructions.
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